Trastuzumab, a monoclonal antibody anti-Her2/neu protein, is a promising agent for the treatment of patients with Her2/neu overexpressing breast cancer, and has also been found to exhibit antitumor activity in human gastric cancer cells that overexpress Her2/neu. Here, ERBB2 is linked to breast carcinoma.